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Abstract
Purpose: Hepatocellular carcinoma (HCC) displays a characteristic hypervascularity and
depends on angiogenesis for tumor growth, which thus provides a potential target for therapeutic
approaches to HCC. In this study, through the use of combined micro-positron emission
tomography (PET)/computed tomography (CT), we investigate if such a combined targeting of
vascular endothelial growth factor (VEGF) activity and expression might retard HCC growth in
an orthotopic intrahepatic xenograft model.
Procedures: Xenograft models were created by intraportal vein injection of HepG2 cell
suspensions in severe combined immunodeficient mice. The mice were then treated with (1)
rapamycin (RAPA), a mammalian target of rapamycin pathway inhibitor; (2) bevazicumab (BEV),
a VEGF monoclonal antibody; and (3) a RAPA/BEV combination.
Results: Assessment of HCC progression using CT with Omnipaque and PET with 2-deoxy-2-
(F-18)-fluoro-D-glucose showed that mice treated with RAPA/BEV had the lowest standardized
uptake values (SUVs). At week 2, mice treated with RAPA/BEV, RAPA, and BEV all showed a
marked decrease in the SUVmax readings with the greatest drop being observed in the RAPA/
BEV group (1.33+0.26, 1.81+0.2, 2.05+0.4 vs. vehicle control 2.11+0.53).
Conclusions: Our results, supported by micro-PET/CT, suggest that RAPA/BEV represents a
potential novel antiangiogenic therapy for the treatment of HCC.
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Introduction
H
epatocellular carcinoma (HCC) is a hypervascular
tumor characterized by neovascularization, which
plays an important role in the growth and progression of
HCC [1]. It is one of the five most common cancers
worldwide, with a particularly high prevalence in Asia due
to endemic hepatitis B virus infection [2]. Curative treat-
ments such as liver resection and transplantation are only
possible if the tumor is detected at an early stage and applies
only to a minority of patients [3]. Prognosis after resection,
however, remains poor due to high incidence of postoper-
ative recurrence, and in addition, transplantation is often
limited by the shortage of grafts [4]. Since conventional
cytotoxic chemotherapy has not shown to be effective
against HCC in both the adjuvant and palliative settings, Correspondence to: Pierce K. H. Chow; e-mail: gsupc@singnet.com.sgthe development of a novel effective therapy for HCC will
be of significant clinical importance [5].
HCC is one of the most vascular solid tumors and
highly dependent on angiogenesis for tumor growth. The
potential of antiangiogenic therapy for HCC is thus
particularly enticing. Rapamycin (Sirolimus) is an inhibitor
of the kinase mammalian target of rapamycin (mTOR)
and possesses both antiproliferative and antiangiogenic
properties [6]. The inhibition of mTOR induces cell cycle
arrest in G1 phase [7, 8]. Rapamycin also inhibits
vascular endothelial growth factor (VEGF) secretion and
VEGF signaling in endothelial cells and impairs tumor
growth by an antiangiogenic mechanism [9]. Another
therapeutic agent with demonstrated anticancer efficacy is
the anti-VEGF antibody bevacizumab. Bevacizumab has
been studied in metastatic renal and colorectal cancers
with promising results [10–12]. However, its effect in
HCC is less conclusively documented.
While the use of animal xenograft models is central to
pre-clinical proof-of-principle studies in experimental oncol-
ogy [13, 14], the correlation between the results of pre-
clinical studies and those of subsequent clinical trials has
been poor [15]. Such in vivo models in oncology research
has traditionally been largely restricted to ectopic models
which are both easy to create and allows direct access for
tumor measurement. The criticism against such ectopic
xenograft models is that they may be poorly representative
of the milieu under which these tumors exist in the patho-
physiological state [16]. While it is possible to create
xenograft tumor models in relevant orthotopic locations
(such as HCC xenografts in intrahepatic sites), they are both
technically challenging to create and there has not been
easily practicable ways to perform serial measurement of
such tumors [17].
Recent developments in pre-clinical bioimaging have,
however, offered a practical means for serial measure-
ment of xenografts in intraperitoneal and other orthotopic
locations. Positron emission tomography (PET) imaging
with 2-deoxy-2-(F-18)-fluoro-D-glucose (
18F-FDG) is
widely used in clinical cancer detection because of the
increase in metabolism found in many tumors [18, 19], and
this has been extended to pre-clinical research [20]. As a
lone modality, there are limitations with
18F-FDG PET
imaging of HCC with some studies reporting a false-
negative rate approaching 50% as well as poor anatomical
localization [21, 22]. Hence, computed tomography (CT)
imaging is an important adjunct to provide confirmatory
support in the diagnosis of HCC [23].
To assess whether the combined suppression of both
VEGF activity by bevacizumab and VEGF expression by
targeting mTOR via rapamycin (RAPA) results in the
inhibition of HCC tumor, we created an orthotopic xenograft
HCC model. The antitumor effect of RAPA/BEV in
xenograft models of HCC was demonstrated by using
micro-PET imaging and evaluation of the standardized
uptake values (SUV) of the tumors and by micro-CT
imaging. Our results provide strong support for the use of
RAPA/BEV as novel antiangiogenic therapy for HCC.
Materials and Methods
Animal Preparation
All animal experiments were approved by the Institutional Animal
Care and Use Committee and carried out in an AAALAC-
accredited facility. Six- to 8-week-old mice, homozygous for the
severe combined immunodeficiency were used. The animals were
provided with sterilized food and water ad libitum and housed in
negative pressure isolators.
HCC Xenograft Model
The HCC cell line HepG2 was acquired from the American Type
Culture Collection. Cells were cultivated in Eagle’s minimum
essential medium (MEM) supplemented with 10% fetal bovine
serum and maintained under a 5% CO2-humidified atmosphere at
37°C. Cells growing exponentially in vitro were trypsinized and
harvested for tumor implantation. All animal manipulations were
performed under sterile conditions. To create orthotopic HCC
models, mice were anesthetized with intraperitoneal injection of a
ketamine/diazepam solution (50 mg/kg ketamine and 5 mg/kg
diazepam) and operated on a pre-warmed operation table. A
subcutaneous dose of baytril 5 mg/kg injection was given before
operative procedure. Briefly, an upper midline laprotomy was
performed. Aided by the use of an operating microscope (Leica,
Switzerland), the portal vein was exposed by displacing the
duodenum through a midline incision of the abdomen and a
suspension of 1×10
6 HepG2 cells in MEM medium was injected
via the portal vein using a 30-gauge needle within a period of a
minute. The abdominal incision was sutured close with 5/0 maxon
(monofilament polyglyconate synthetic absorbable suture) and skin
was closed with 5/0 prolene (polypropylene suture). Postoperatively,
the mice were given a subcutaneous injection of 5 mg/kg caprofen
for analgesia. The animals were kept warm and returned to their
cages when fully awake. PET scanning was performed on the mice
periodically after day 4.
Micro-PET Imaging Using
18F-FDG
Prior to micro-PET imaging, the mice were fasted overnight until
imaging was completed, with water being available ad libitum. On
the day of imaging, the mice were pre-warmed to a body
temperature of 37°C before an approximate 150 μCi of
18F-FDG
(0.6 mM) was administered intraperitoneally. The body temperature
was maintained at 37°C throughout the uptake period. Micro-PET
imaging was performed with the R4 micro-PET scanner (Con-
cordes Microsystems Inc.) 45 min after
18F-FDG injections. The
specification of the R4 micro-PET scanner is briefly as follows: it
has a ring diameter of 26 cm and a 7.8-cm axial field of view and
the intrinsic spatial resolution ranges from 1.56 to 2.01 mm, with a
mean of 1.75 mm. The reconstructed resolution is 1.8 mm full
width at half maximum in the center of the field of view and 3 mm
at 4 cm radial offset.
Each mouse was imaged for 10 min. During the micro-PET
imaging, the mice were placed in an imaging chamber and kept
under isoflurane anesthesia.
18F-FDG was obtained from the
Department of Nuclear Medicine of Singapore General Hospital.
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Images were reconstructed using filtered backprojection without
scatter or attenuation correction. For cross-calibration of the dose
calibrator and the micro-PET scanner, a 25-cm
3 cylinder phantom
filled with known concentration of
18F-FDG was imaged. From this
scan, a system calibration factor was derived by dividing the known
activity concentration in the phantom by the measured mean counts
per voxel in the reconstructed PET images.
Quantitative Image Analysis
Regions of interest were manually drawn over the tumors. Tracer
uptake by the various tumors were quantified by maximum
standardized uptake values (SUVmax) using the formula: SUVmax =
maximum tissue activity concentration (μCi/ml)/injected dose
(μCi) × body weight (g).
Animal Preparation and Micro-CT Imaging
Images were obtained on a Rigaku micro-CT scanner (JMorita
Engineering Co., Ltd, Japan). This is a dedicated CCD plate small
animal micro-CT scanner with a bore diameter of 10 cm. The X-ray
voltage was set at 90 kVp and an anode current of 88 μA. Images
of the whole animal were obtained after one revolution that lasted
17 s. The minimum pixel size is 48×48×36 μm. Mice were fasted
before the scan to minimize imaging artifacts due to minerals that
are found in rodent chow. Three hours prior to the scan, mice were
given an intraperitoneal bolus dose of 20 ml/kg of Omnipaque 300.
The mice received 5% isoflurane in oxygen during rapid inhalation
induction anesthesia (1–2 min). Maintenance of anesthesia during
each scan was achieved using 1–2% isoflurane in oxygen. The total
scan time for each scan is 2 min.
Determination of HCC Xenograft Progression
in an Orthotopic Intrahepatic Model
The progression of the orthotopic HCC xenograft models was
determined by imaging mice inoculated with HepG2 cells at
different time points. Mice were killed at days 0, 4, 7, and 10 after
tumor cells inoculation following the completion of imaging on
those days. Histology (see below) was performed to correlate tumor
progression with micro-PET results. A total of 24 mice were used.
Drug Treatment
Four days after tumor cell inoculation, HCC xenograft mice
were randomized into one of four groups and treated as
follows: (1) intraperitoneal injection with 100 μlo fs a l i n e
(vehicle/control), (2) oral administration of RAPA (Rapamune,
Wyeth Pharmaceuticals Company, Guayama) at 1 mg/kg, (3)
intraperitoneal injection of 5 mg/kg bevacizumab (BEV,
Avastin, Genentech, Inc., South San Francisco, CA, USA),
and (4) combined oral RAPA and injected BEV (BEV/RAPA).
Control and BEV injections were performed on a fortnightly
basis while oral RAPA was administered daily. Each group
involved 13 independent tumor-bearing mice. Body weights,
ascites formation, and overall survival were monitored twice
weekly. Tumor-bearing mice were sacrificed when they
became moribund and the presence of ascitic fluid was
recorded for each mouse. At the end of the treatment regimen,
all animals were sacrificed and tumors harvested for histo-
logical analysis.
Histology and Immunohistochemical Analysis
The mice were killed with overdosage of pentobarbitone. Livers
were harvested in 4% buffered formaldehyde for 24 h, processed
into paraffin, then sectioned at 3 μm. Sections were deparaffinized
with xylene, degrading alcohol 100%, 95%, and 70%, and water,
and finally stained with hematoxylin and eosin (H&E).
For immunoreactivity staining, 5-μm deparaffinized polysin-
coated sections were treated with 3% hydrogen peroxide for non-
specific binding. Two types of antibody were employed for
immunohistochemical staining. Ki-67, rabbit monoclonal antibody,
and vascular endothelial growth factor, epitope-specific rabbit
antibodies, were from Lab Vision Corp, USA. The antibody against
VEGF could cross-react with both mouse and human proteins. Both
were revealed using the peroxidase–antiperoxidase technique by
Chemmate Envision Kit HRP/DAB.
Visual Grading of Ki-67 and VEGF Protein
Expression
The expressions of Ki-67 and VEGF proteins within all sections
were quantified by a visual grading score [24]. The proliferation
index was determined by calculating the number of Ki-67-positive
cells per total number of cells in ten fields at ×40 magnification and
expressing it as a percentage. All sections were graded on three
separate occasions by three different investigators. If the grade
varied between scoring runs, the results of the latter analysis were
chosen because this was considered more accurate. An overall
estimate of the intensity was used rather than quantifying the
regions of highest expression.
Statistical Analysis
Body weight, Ki-67 expression, and SUV differences were analyzed
by one-way ANOVA. Differences in survival were evaluated by the
Kaplan–Meier method and compared by a log-rank test.
Results
Progression of HCC Xenograft in an Orthotopic
Intrahepatic Model
Mice inoculated with HepG2 cells via intraportal vein
injection were subjected to micro-PET scanning to confirm
successful tumor transplantation. Micro-PET scanning
showed successful tumor implantation for all inoculated
mice. A total of 24 mice were used and randomized into four
groups to be sacrificed at various time points. As shown by
Fig. 1a, b, by day 4, micro-PET scanning revealed a
metabolically active lesion in the liver (SUVmax=1.88±
0.13). By day 7, the SUVmax reading had increased to 2.44±
0.17. Subsequent SUVmax readings continued to rise with
the mice becoming increasingly weak clinically. H&E
histological analysis corresponded with the SUVmax readings
thus supporting the use of micro-PET as a diagnostic tool in
translational research.
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B a s e do nt h er e s u l t so fF i g .1, we have chosen to
commence drug treatment 4 days after tumor cells
inoculation. In general, there was a significant reduction
(p valueG0.05) in the SUVmax readings of the mice
undergoing RAPA/BEV treatment when compared to the
other three groups of mice (Fig. 2a). One week after
tumor cells inoculation, mice treated with RAPA/BEV
had the lowest SUVmax reading of 1.8±0.29. Mice
treated with RAPA and BEV had a reading of 2.42±
0.37 and 2.18±0.1, respectively. Vehicle control mice
had a SUVmax reading of 1.9±0.2. At week 2, all mice,
with the exception of control mice, showed a marked
decrease in the SUVmax readings. Mice treated with
RAPA/BEV had a low SUVmax reading of 1.33±0.26,
followed by those treated with RAPA (1.81±0.2) and
BEV (2.05±0.4). On the other hand, SUVmax readings of
control mice increased from 1.9±0.2 to 2.11±0.5. From
week 3 onwards, mice treated with single drug agent
(RAPA or BEV) showed significantly higher SUVmax
readings compared to vehicle control. Such higher read-
ings were, however, contributed by a very small volume
of the tumor cells as indicated by micro-PET analysis.
We speculate that this could be due to widespread
necrosis that was observed in the control mice, thus
accounting for the lower SUVmax readings. Despite this,
at week 3, there was still a 43.0±5.2% and at week 4, a
31.7±5.3% reduction in the SUVmax readings in the
RAPA/BEV-treated mice compared to the control mice.
Besides the drop in SUVmax readings, it is also obvious
Fig. 1. a Coronal
18F-FDG images of representative mice bearing HCC xenograft tumor over time. Images obtained on a
dedicated small animal micro-PET scanner depicted tumor progression. At day 0,
18F-FDG was mainly taken up by the heart
and lungs. However, as tumor progresses, the glucose analogue concentrates in the actively metabolizing HCC. b SUVmax
readings of HCC xenograft tumors after inoculation. Error bar shows SEM.
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ing combined RAPA/BEV chemotherapy exhibited less
extensive spread of the tumor cells (Fig. 2b).
Similarly, CT imaging with Omnipaque reveals a well-
defined liver in the normal mice. In the vehicle control
animals, large tumor nodules were detected. In addition,
large volumes of ascites were also observed. In contrast, the
RAPA/BEV group had a smaller tumor volume on the CT
image and almost no ascites were detected. Taken together,
these possibly indicate that the drugs had a synergistic effect
in slowing down the metabolic rate of HCC tumor cells and
hence limiting its spread.
Fig. 2. a SUVmax readings of HCC over time. Mice were subjected to PET imaging weekly after tumor inoculation and their
SUVmax readings calculated. Error bars show SEM. b Representative PET and CT images of HCC mice with and without drug
treatment. Top panels depict tumor metabolic activity by micro-PET imaging after a single dose administration of approximate
150 μCi of
18F-FDG. Bottom panels show CT images after an intraperitoneal bolus dose of 20 ml/kg of Omnipaque 300. Similar
results were obtained for each of the 13 mice in each group.
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To provide further support for the effectiveness of the use of
combined RAPA/BEV treatment, we performed histological
analysis on the dissected tumors (Fig. 3). Widespread
necrosis was also predominantly found in the control mice
but was minimal in the RAPA/BEV group. This also
confirms our previous speculation that the lower SUVmax
readings exhibited by the control group as compared to mice
treated with only RAPA or BEV were due to large volume
of necrotic liver.
Immunohistochemical analysis with Ki-67 revealed sim-
ilar results as H&E staining. Cell proliferation was most
abundant in vehicle control mice followed by single drug
Fig. 3. Phenotypical effects and histological analysis of RAPA, BEV, and RAPA/BEV in HCC xenografts. Shown are
representative livers (a–e) and histological sections (f–t) for HepG2 HCC xenografts. Xenografts were randomized into one of
the four treatment groups and treated with vehicle (control), RAPA (1 mg/kg), BEV (5 mg/kg), or combined RAPA/BEV. All
treatments were initiated 4 days after cell inoculation. a–e Effects on gross tumor morphology. f–j Histological sections, stained
with hematoxylin and eosin (H&E) at ×20 magnification. Tumors treated with single drug agent, BEV and RAPA, and vehicle
control consisted mainly of dysplastic hepatocytes when compared to tumors treated with combined RAPA/BEV. Liver
cirrhosis was also observed in the group treated with vehicle control. Immunohistochemical analysis of Ki-67 (k–o), and VEGF
(p–t) and CD31 (u–y). Mice treated with RAPA/BEV showed the most dramatic decrease in Ki-67 (cell proliferation) when
compared to vehicle control mice. VEGF protein was found to be expressed in both non-cancerous liver as well as HCC. VEGF
expression is was stronger in well-differentiated HCC cells and dyplastic nodules than in normal hepatocytes. In poorly
differentiated HCC, VEGF protein is expressed by the endothelial cells lining intratumoral vessels. CD31 was not detected in
both the normal mice as well as mice treated with combined RAPA/BEV. In mice treated with single agent RAPA as well as
those that received vehicle control, CD31 was expressed in the sinusoids of the HCC cells.
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of 69.8±4.6 while mice treated with RAPA had an index of
46.4±10.1 (p valueG0.05) and those treated with BEV had
an index of 44.0±10.4 (p valueG0.05). Mice that received
the combined therapy had an almost twofold reduction in the
index (29.6±8.6, p valueG0.001).
On the other hand, VEGF expression was detected in both
HCC cells as well as non-cancerous hepatocytes. VEGF was
expressed faintly in the cytoplasm of hepatocytes of back-
ground liver. In the HCC cells, the expression of VEGF
correlates negatively with the degree of cell differentiation.
Mice that received the combined therapy had staining pattern
that resembled closely to mice without HCC. In contrast,
vehicle control mice showed strongly stained cells sur-
rounded by layers of unstained HCC cells. In the BEV group,
patches of strongly stained HCC cells were observed. Finally,
mice treated with single agent RAPA had staining pattern
intermediate of vehicle control mice and BEV-treated group.
In contrast to VEGF, CD31 was most abundantly
expressed in the sinusoids of vehicle control mice. In mice
that received either single agent therapy, CD31 was found to
beexpressedmoreinthosetreatedwithRAPAthanthosewith
BEV. This probably reflected sinusoidal capillarization, thus
indicating the effectiveness of the respective drug therapy.
Hence, by combining the use of bioimaging techniques as
well as histological analysis, we have shown that the
combined RAPA/BEV chemotherapy is effective against
HCC xenograft in the murine model.
RAPA/BEV Inhibits Malignant Ascites
and Prolongs Survival
In this study, we developed an orthotopic intrahepatic model
that strongly reflects clinical HCC. Within 3 weeks of tumor
inoculation, control mice developed large volumes of ascites
(3–4 ml). This was in sharp contrast with those that had
received drug treatment. Unlike the control group, only one
of the mice receiving RAPA/BEV treatment exhibited mild
abdominal swelling at the end of week 5. In the single drug
treatment group, mice developed swollen abdomen only at
week 4 and on dissection, an approximate volume of 1–2m l
of ascitic fluids could be extracted. Kaplan–Meier survival
analysis (Fig. 4) provides further support for the efficacy of
the drugs. RAPA/BEV-treated mice had a significantly
prolonged overall survival. No significant effects on body
weight, morbidity, or severe toxicity were observed in the
RAPA/BEV treatment groups
Discussion
In this orthotopic xenograft model, mice treated with RAPA/
BEV had slower HCC growth and less ascites than untreated
animals. Our results show that the combined use of
rapamycin and bevacizumab prevents the progression of
HCC and improves overall survival. The combined suppres-
sion of both VEGF activity by bevazicumab and VEGF
expression via rapamycin probably induces both additive
and synergistic inhibition on HCC growth and angiogenesis.
VEGF is known to play a significant role in the early
stage of hepatocarcinogenesis although its exact mechanism
remains unclear [1]. Its expression increases gradually from
low-grade dysplastic nodules to high-grade dysplastic
nodules to early HCC [24]. A possible mechanism by which
VEGF is involved in liver carcinogenesis is VEGF synthesis
by hepatocytes adjacent to the tumor nodule under the
influence of tumor-released cytokines and growth factors
[25]. Indeed, there have been numerous findings indicating
VEGF over-expression in the cirrhotic liver of patients with
a HCC, compared to cirrhotic livers without HCC [25, 26].
Hence, it is possible to target the proliferating endothelial
cells instead of cancer cells. There are several advantages of
antiangiogenic therapy over conventional cytotoxic chemo-
therapy. As microvascular endothelial cells are genetically
stable cells that are less prone to mutation, drugs targeted at
them are less likely than cytotoxic drugs to induce drug
resistance. In addition, the problem of drug delivery to tumor
cells can be easily overcome since endothelial cells are
directly exposed to blood-borne agents. This is in sharp
contrast with conventional anticancer therapy. Finally, due
to the specificity of the antiangiogenic therapy towards
immature characteristics of tumor vasculature, which differs
from normal quiescent vasculature, low toxicity has been
demonstrated in pre-clinical studies [27].
There are now increasing evidence in pre-clinical studies
that antiangiogenic therapy using different approaches can
inhibit the growth of HCC in synergistic manners. Recent
clinical trials have shown the efficacy of bevacizumab in
combination with chemotherapy in treating various types of
human cancers [28–30]. In a recent report by Semela and
coworkers, they have concluded using an orthotopic,
Fig. 4. Effects of RAPA/BEV on HCC xenograft mice. Each
group comprised 13 animals. Kaplan–Meier analysis shows
that mice with RAPA/BEV treatment had a significant higher
survival rate than those that received either single-arm
treatment or without treatment.
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blockage of tumor angiogenesis and impaired HCC growth
[31]. In our study, we combined the use of both bevacizu-
mab and rapamycin. We speculate that besides suppressing
VEGF expression from HCC tumor cells, rapamycin might
possibly inhibit proliferation of endothelial cells and blocked
angiogenesis. As such, the use of a combined RAPA/BEV
might provide a potent antiangiogenic therapy for retardation
of HCC progression. Many studies have suggested that HCC
originates as a well-differentiated tumor and becomes
progressively less differentiated with enlargement [32]. Our
immunohistochemistry staining of VEGF showed that only
the vehicle control mice eventually developed advanced
HCC characterized by poorly differentiated HCC tissues
surrounded by well-differentiated HCC tissues. Although
mice treated with either single agent did not exhibit
advanced HCC, they nonetheless displayed “patchy” strong
expression of VEGF, especially in mice treated with RAPA
only. All these results further strengthened our hypothesis
that combined RAPA/BEV is effective in preventing HCC
progression.
Our paper is also novel in that it compares the diagnostic
values of micro-PET/CT and conventional histological
analysis. Although histological analysis is extremely useful
and accurate at diagnosing or even staging diseases such as
HCC, its procedures are usually long and tedious and require
expertise to interpret the results. This is true in clinical
practice as well. Despite being the most definite assessment
of HCC grading, histological examination using percuta-
neous needle biopsy is invasive and the specimen retrieved
does not always represent the entire lesion due to sampling
errors [33]. Moreover, the prognosis and survival of patients
with HCC is heavily dependent on the disease stage at the
time of diagnosis. Currently, alpha-fetoprotein (AFP) is the
only serological marker that is available for the detection of
HCC clinically. Although minimally invasive, it is not a
sufficiently reliable marker because of its poor sensitivity
[34]. Moreover, its level varies between ethnic groups and is
also not recommended for diagnosis of HCC in non-cirrhotic
patients [35, 36]. In a study by Giannelli et al. [34], only a
small percentage of patients showed AFP values that are
reflective of HCC. Several other reports have also indicated
that the AFP sensitivity range from 47% to 68% [37].
On the other hand, the use of bioimaging modalities
overcomes all these obstacles. Compared with conventional
single bioimaging modality such as CT, MRI, or ultra-
sonography, dual PET/CT with
18F-FDG has advantages in
the evaluation of hepatic malignancies, including diagnosing,
staging tumors, evaluating biologic characters, and monitor-
ing tumor progression. Byoffering a combined functional and
anatomical analysis, PET/CT has been increasingly used in
clinical practice since it is more sensitive and specific than
either PET or CT alone [38]. Salem and coworkers have
recently reported the correlation between
18F-FDG uptake in
woodchuck HCCs and the tumor differentiation level [31].
Similarly, our results derived from micro-PET/CT also
corresponded with that of standard histology analysis. Such
findings have great impact on future experimental design.
With the use of bioimaging modalities such as micro-PET
and micro-CT, histological analysis at every stage is no
longer critical, allowing serial follow-up and assessment of
each animal into the last stages of the disease.
The objectives of this study were to evaluate the efficacy
of the combined RAPA/BEV antiangiogenic therapy as well
as to assess the performance of
18F-FDG-PET in an
orthotopic xenograft HCC model. Our results clearly
illustrate that pharmacological inhibition of the mTOR with
rapamycin and specific targeting of VEGF with bevacizu-
mab may provide an effective novel treatment for HCC. In
addition, the use of micro-PET/CT may prove to be an
excellent research tool to monitor progression of orthotopic
cancer models in testing therapy efficacies.
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